
Viatris, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals
2025-10-27 15:48:38Viatris, Inc. has recently revised its evaluation amid fluctuating market conditions, with its stock priced at $10.35. The company has experienced significant volatility over the past year, with mixed technical indicators and varied performance compared to the S&P 500, reflecting both challenges and opportunities in the pharmaceutical sector.
Read More
Viatris Stock Forms Golden Cross, Signaling Potential Bullish Breakout Ahead
2025-09-25 16:58:36Viatris, Inc. has recently experienced a Golden Cross, indicating a potential shift in momentum. The stock rose 1.15% today, contrasting with the S&P 500's decline. However, Viatris's longer-term performance remains challenging, with significant declines over the past year and five years, suggesting caution for investors.
Read MoreIs Viatris, Inc. technically bullish or bearish?
2025-09-20 20:05:07As of 25 August 2025, the technical trend for Viatris, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by daily moving averages and a bearish monthly MACD. Weekly indicators show mixed signals with the MACD and KST bullish, while the Bollinger Bands indicate a mildly bullish stance. However, the overall weakness is reflected in the Dow Theory and OBV, both showing mildly bearish trends. In terms of performance, Viatris has underperformed the S&P 500 across multiple periods, with a year-to-date return of -20.80% compared to the S&P 500's 12.22%, and a 1-year return of -17.14% against the S&P 500's 17.14%....
Read MoreIs Viatris, Inc. overvalued or undervalued?
2025-09-20 18:38:01As of 9 May 2024, the valuation grade for Viatris, Inc. has moved from expensive to risky, indicating a shift in perception regarding its market valuation. The company appears to be overvalued, as evidenced by a P/E ratio of 38, which is significantly higher than the peer Walgreens Boots Alliance, Inc. at -14.12. Additionally, Viatris has an EV to EBITDA ratio of 6.47 and a Price to Book Value of 0.67, suggesting that its market price does not adequately reflect its underlying asset value. In comparison to its peers, Viatris's valuation metrics indicate a concerning position, particularly with a return on equity (ROE) of only 1.75% and a return on capital employed (ROCE) of 2.82%. Furthermore, the company's stock has underperformed relative to the S&P 500 across multiple time frames, with a year-to-date return of -20.80% compared to the S&P 500's 12.22%. This trend reinforces the notion that Viatris is cur...
Read More





